Tiziana Life Sciences plans to assess intranasal foralumab for long Covid
Pharmaceutical Technology
APRIL 14, 2023
Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid. Foralumab is a fully human anti-CD3 monoclonal antibody, which works by binding to the T-cell receptor and regulating T-cell function to reduce pulmonary inflammation.
Let's personalize your content